Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

completed250%
terminated125%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruiting

FDG PET/CT in Breast Cancer Bone Mets

NCT01996046
completedphase_2

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

NCT03089606
completednot_applicable

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

NCT00606294
terminatednot_applicable

PET-CT Scans in Healthy Volunteers After Flu Vaccination

NCT00769002

Clinical Trials (4)

Showing 4 of 4 trials
NCT01996046

FDG PET/CT in Breast Cancer Bone Mets

Active Not Recruiting
NCT03089606Phase 2

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Completed
NCT00606294Not Applicable

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

Completed
NCT00769002Not Applicable

PET-CT Scans in Healthy Volunteers After Flu Vaccination

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4